		·
1		
2		DEFORE THE
3	COMMUNICA	BEFORE THE ATIONS SUBCOMMITTEE OF THE
4		CITIZENS' OVERSIGHT COMMITTEE TO THE
5	ORGA	TITUTE FOR REGENERATIVE MEDICINE ANIZED PURSUANT TO THE
6	CALIFORNIA S	TEM CELL RESEARCH AND CURES ACT
7		REGULAR MEETING
8		
9		
10		
11		
12	LOCATION:	VIA ZOOM
13		
14	DATE:	SEPTEMBER 18, 2024
15	DATE:	3 P.M.
16		
17	REPORTER:	RETH C DRAIN CA CSR
18	KEI OKI EK.	BETH C. DRAIN, CA CSR CSR. NO. 7152
19		
20	FILE NO.:	2024-37
21	. 122	
22		
23		
24		
25		

INDEX

ITEM DESCRIPTION	PAGE NO.
OPEN SESSION	
1. CALL TO ORDER	3
2. ROLL CALL	3
3. COMMUNICATIONS TEAM UPDATE: PROGRESS ON THE IMPLEMENTATION OF THE 2023-2024 COMMUNICATIONS PLAN	5
4. PUBLIC COMMENT	NONE
5. ADJOURNMENT	44

	DETH G. DRAIN, GA GSR NO. 7 132
1	SEPTEMBER 18, 2024; 3 P.M.
2	
3	CHAIRPERSON BONNEVILLE: OKAY. WHY DON'T
4	WE CONVENE THE MEETING. IF YOU WANT TO START THE
5	RECORDING.
6	WELCOME, EVERYONE, TODAY TO OUR
7	COMMUNICATIONS SUBCOMMITTEE MEETING. AND I WOULD
8	ASK CLAUDETTE TO TAKE THE ROLL, OR IS SCOTT TAKING
9	ROLL?
10	MS. MANDAC: KIM BARRETT. GEORGE
11	BLUMENTHAL. MARIA BONNEVILLE.
12	CHAIRPERSON BONNEVILLE: PRESENT.
13	MS. MANDAC: LEONDRA CLARK-HARVEY. YSABEL
14	DURON.
15	MS. DURON: PRESENT.
16	MS. MANDAC: ELENA FLOWERS. DAVID
17	HIGGINS.
18	DR. HIGGINS: HERE.
19	MS. MANDAC: VITO IMBASCIANI.
20	CHAIRMAN IMBASCIANI: HERE.
21	MS. MANDAC: PAT LEVITT. LINDA MALKAS.
22	CHAIRPERSON BONNEVILLE: SHE'S WAVING.
23	SHE'S HERE.
24	MS. DURON: IS THAT PHYSICAL THERAPY,
25	LINDA?
	3

	, , , , , , , , , , , , , , , , , , ,
1	MS. MANDAC: CHRIS MIASKOWSKI.
2	DR. MIASKOWSKI: HERE.
3	MS. MANDAC: LAUREN MILLER-ROGEN.
4	MS. MILLER-ROGEN: HERE.
5	MS. MANDAC: ELENA FLOWERS.
6	DR. FLOWERS: PRESENT.
7	MS. MANDAC: BACK TO YOU, MARIA.
8	CHAIRPERSON BONNEVILLE: THANK YOU SO
9	MUCH. I BELIEVE YSABEL WANTED TO MAKE A COMMENT
10	BEFORE WE STARTED THE BUSINESS OF THE DAY.
11	MS. DURON: YES. THANK YOU VERY MUCH,
12	MARIA. I'M STILL FEELING A LITTLE I RELINQUISHED
13	MY DUTIES BECAUSE I'M STILL FEELING A LITTLE UNDER
14	THE WEATHER AFTER MY FIRST BOUT WITH COVID.
15	WHAT I REALLY WANTED TO DO THIS MOMENT WAS
16	TO TAKE A MINUTE TO RECOGNIZE THE RECENT PASSING OF
17	OUR BOARD MEMBER AND FRIEND FRED FISHER. HE WAS A
18	PASSIONATE ADVOCATE FOR THE CAUSE OF ALD AND
19	MULTIPLE SCLEROSIS. HE WAS A DEDICATED, OUTSPOKEN,
20	AND COMMITTED PUBLIC SERVANT FOR CIRM WHO TAUGHT ME
21	HOW TO APPRAISE GOVERNANCE AND OTHER ISSUES BEFORE
22	THE BOARD. AND HE WILL BE MISSED. THANK YOU,
23	MARIA.
24	CHAIRPERSON BONNEVILLE: THANK YOU,
25	YSABEL. AND WE WILL ALSO BE HONORING FRED AT THE

1	BOARD MEETING NEXT WEEK. SO I WELCOME ALL BOARD
2	MEMBERS TO BRING COMMENTS AND STORIES ABOUT FRED SO
3	WE'LL START OFF THE MEETING. AND WE'VE ALSO INVITED
4	HIS FAMILY TO JUST LISTEN IN AND JUST KNOW HOW MUCH
5	WE APPRECIATED HIM. SO HOPEFULLY THEY WILL BE ABLE
6	TO LISTEN IN TO THAT.
7	KOREN, I PASS THIS ALONG TO YOU FOR THE
8	COMMUNICATIONS TEAM UPDATE.
9	MS. TEMPLE-PERRY: YES. I JUST WANT TO
10	THANK YOU, MARIA AND YSABEL. GOOD AFTERNOON,
11	EVERYONE, AND WELCOME THE COMMUNICATION SUBCOMMITTEE
12	MEETING. WE'RE JUST GETTING THE SLIDES UP SO YOU
13	ALL CAN READ THEM EASILY.
14	SO FOR TODAY I'M EXCITED TO SHARE A NUMBER
15	OF UPDATES TO OUR ONGOING PROJECTS AND INITIATIVES
1.0	AC WELL AS FUTURE DIANS OUTLINED IN OUR
16	AS WELL AS FUTURE PLANS OUTLINED IN OUR
16 17	COMMUNICATIONS STRATEGY.
17	COMMUNICATIONS STRATEGY.
17 18	COMMUNICATIONS STRATEGY. AND SO FIRST, AS ALWAYS, I'D LIKE TO
17 18 19	COMMUNICATIONS STRATEGY. AND SO FIRST, AS ALWAYS, I'D LIKE TO INTRODUCE OUR TEAM. TYPICALLY I LIKE THEM TO
17 18 19 20	COMMUNICATIONS STRATEGY. AND SO FIRST, AS ALWAYS, I'D LIKE TO INTRODUCE OUR TEAM. TYPICALLY I LIKE THEM TO INTRODUCE THEMSELVES; BUT SINCE WE ONLY HAVE AN HOUR
17 18 19 20 21	COMMUNICATIONS STRATEGY. AND SO FIRST, AS ALWAYS, I'D LIKE TO INTRODUCE OUR TEAM. TYPICALLY I LIKE THEM TO INTRODUCE THEMSELVES; BUT SINCE WE ONLY HAVE AN HOUR TODAY, I'M GOING TO INTRODUCE EACH ONE. AGAIN, MY
17 18 19 20 21 22	COMMUNICATIONS STRATEGY. AND SO FIRST, AS ALWAYS, I'D LIKE TO INTRODUCE OUR TEAM. TYPICALLY I LIKE THEM TO INTRODUCE THEMSELVES; BUT SINCE WE ONLY HAVE AN HOUR TODAY, I'M GOING TO INTRODUCE EACH ONE. AGAIN, MY NAME IS KOREN TEMPLE-PERRY. I AM THE SENIOR
17 18 19 20 21 22 23	COMMUNICATIONS STRATEGY. AND SO FIRST, AS ALWAYS, I'D LIKE TO INTRODUCE OUR TEAM. TYPICALLY I LIKE THEM TO INTRODUCE THEMSELVES; BUT SINCE WE ONLY HAVE AN HOUR TODAY, I'M GOING TO INTRODUCE EACH ONE. AGAIN, MY NAME IS KOREN TEMPLE-PERRY. I AM THE SENIOR DIRECTOR OF MARKETING AND COMMUNICATIONS HERE AT

1	DESAI, WHO IS OUR COMMUNITY OUTREACH MANAGER; KATIE
2	SHARIFY IS OUR COMMUNICATIONS TEAM COORDINATOR; AND
3	CHRISTINA SMITH IS OUR SOCIAL MEDIA AND CONTENT
4	SPECIALIST. I'D ALSO LIKE TO RECOGNIZE WE HAVE
5	ANOTHER MEMBER ON OUR CALL TODAY, JACQUELINE
6	HANTGAN, WHO IS OUR SENIOR ADVISOR OF OUTREACH. AND
7	SO SHE'S HERE TODAY ALSO TO PROVIDE ADDITIONAL
8	PERSPECTIVE ON SOME OF OUR EFFORTS. SO THANK YOU.
9	SO TO GUIDE OUR DISCUSSION TODAY, I WANTED
10	TO PROVIDE AN AGENDA OF THE TOPICS WE WILL COVER.
11	AS I MENTIONED, WE'RE GOING TO HIGHLIGHT SEVERAL
12	PROJECTS WE'VE BEEN WORKING ON THE PAST FEW MONTHS
13	ACROSS VARIOUS CHANNELS FROM PRINT TO DIGITAL TO
14	SOCIAL PROJECTS. AND THEN WE WOULD LIKE TO SHOWCASE
15	A NUMBER OF OUTCOMES FROM OUR OUTREACH CAMPAIGNS AND
16	EVENTS. AND THEN I'D LIKE TO PROVIDE AN OPPORTUNITY
17	FOR DISCUSSION AND FOR QUESTIONS.
18	ALL RIGHT. SO TO GET STARTED TODAY, WE
19	ARE VERY EXCITED TO SHARE WITH YOU A SNEAK PEAK OF
20	OUR UPCOMING ANNUAL REPORT. AND SO IN HONOR OF OUR
21	20TH ANNIVERSARY, WE'VE CENTERED THIS YEAR'S THEME
22	ON CIRM'S CONTRIBUTIONS AND IMPACTS IN THE FIELD.
23	YOU CAN ACTUALLY SEE A NICE SCREENSHOT OF OUR COVER
24	FOR THE ANNUAL REPORT. AND SO THIS YEAR'S THEME IS
25	"OUR JOURNEY FORWARD: HOW CIRM CATALYZES

1	REGENERATIVE MEDICINE TODAY AND BEYOND." AND IT
2	REALLY REFLECTS THE MILESTONES WE'VE ACHIEVED AND
3	REALLY SHOWCASES CIRM AS A DRIVING FORCE IN
4	ADVANCING THE FIELD. THIS IS A VERY ROBUST ANNUAL
5	REPORT THIS YEAR. WE'VE BEEN WORKING ON IT FOR A
6	NUMBER OF MONTHS. SO IT CROSSED 36 PAGES. WE'VE
7	INCLUDED PATIENT STORIES, MILESTONES, TIMELINES, AS
8	WELL AS QUOTES FROM LEADERS IN THE FIELD REALLY
9	REFLECTING ON OUR INFLUENCE.
10	AND SO WE ARE IN THE FINAL STAGES OF OUR
11	ANNUAL REPORT. WE ARE FACT CHECKING NUMBERS AND
12	SPECIFIC INFORMATION, AND WE ARE PREPARING IT FOR A
13	FINAL REVIEW. AND SO AS PART OF OUR ROLLOUT, IN THE
14	NEXT COUPLE OF WEEKS, WE WILL DISTRIBUTE IT ACROSS
15	TO OUR PARTNERS. IT'S GOING TO GO TO ALPHA CLINICS
16	AS WELL AS THOSE WE HAVE FEATURED IN THE ANNUAL
17	REPORT.
18	SIMILAR TO LAST YEAR, WE'RE GOING TO
19	TRANSLATE THE ANNUAL REPORT TO SPANISH. AND WE HAVE
20	PLANS TO CREATE A CUSTOM DIGITAL LANDING PAGE AS
21	WELL AS AN ONLINE VIEW BOX TO FACILITATE EASY
22	VIEWING.
23	ANOTHER EXCITING UPDATE. AT OUR LAST
24	SUBCOMMITTEE MEETING, WE DISCUSSED THE NEED TO
25	DEVELOP A STATEWIDE NEWSLETTER TO REACH AND ENGAGE

1	DIVERSE COMMUNITIES. AND THIS WAS A KEY INITIATIVE
2	THAT WAS OUTLINED IN OUR COMMUNICATIONS STRATEGY.
3	AND AS A REMINDER, THE INITIATIVE REALLY AIMS TO
4	DEEPEN OUR ENGAGEMENT WITH VARIOUS COMMUNITIES AS
5	WELL AS PROVIDE UPDATES ON RESEARCH AND REALLY TO
6	STRENGTHEN OUR RELATIONSHIPS WITH KEY PARTNERS.
7	SO WE'VE MET INTERNALLY WITH THE PATIENT
8	ACCESS TEAM. WE'VE HAD A WONDERFUL TIME DIGGING
9	THROUGH THIS PUBLICATION. WE HAVE NAMED IT CIRM
10	COMMUNITY CONNECTIONS. AND SO WE ACTUALLY WENT
11	THROUGH A PROCESS OF DEVELOPING THE BRANDING, WHICH
12	YOU SEE HERE TO THE RIGHT IS THE EMAIL DIGITAL
13	VERSION OF THIS, AND THEN TO THE LEFT IS THE ACTUAL
14	PRINT MOCK-UP OF THIS. AND SO FOR RIGHT NOW WE ARE
15	DEVELOPING OUR EDITORIAL CALENDAR WITH A PLAN TO
16	LAUNCH THE EMAIL VERSION OF THIS NEWSLETTER THIS
17	FALL.
18	THERE'S GOING TO BE A HEAVY EMPHASIS ON
19	SOCIAL MEDIA PROMOTION TO AMPLIFY ITS LAUNCH. AND
20	THEN BY WINTER 2025, WE ARE GOING TO DISTRIBUTE A
21	PRINT EDITION OF THIS PUBLICATION, AGAIN, TO OUR
22	VARIOUS PARTNERS. REALLY IT'S REALLY GOING TO BE A
23	VALUABLE RESOURCE TO SHARE STORIES OF IMPACT AS WELL
24	AS TO SPOTLIGHT OUR ONGOING RESEARCH EFFORTS. SO
25	WE'RE REALLY EXCITED ABOUT THIS PUBLICATION.

1	MS. SHARIFY: KOREN, I'LL TAKE THAT FROM
2	HERE. IN ADDITION TO THE HIGHLIGHTING OF THE GRANTS
3	AWARDS AND THE RESEARCH THAT THE AGENCY FUNDS, WE'RE
4	ALSO VERY DEDICATED TO SHARING PATIENT STORIES. AND
5	THAT'S BEEN ONE OF OUR MAIN STRATEGIES WHICH WE'VE
6	SEEN THAT IS VERY HELPFUL AND ENGAGING OUR READERS
7	BOTH ON THE BLOG AND OUR SOCIAL MEDIA TO REALLY GIVE
8	PEOPLE AN IDEA OF WHAT THE REAL-WORLD EFFECT OF WHAT
9	THE RESEARCH THAT WE SUPPORT, THE DIFFERENCE THAT IT
10	MAKES IN THE LIVES OF THE PATIENTS.
11	ONE OF THE STORIES IS FROM JAKE JAVIER.
12	JAKE WAS IN A TRIAL RIGHT BEFORE HIS HIGH SCHOOL
13	GRADUATION AFTER HE HAD A SPINAL CORD INJURY. HE
14	HAS BEEN HAVING A LOT OF IMPROVEMENT AND REALLY JUST
15	LIVING HIS LIFE AND GRADUATING COLLEGE, GOING TO
16	EARN HIS MASTER'S, AND HE IS WORKING NOW. HE'S
17	GETTING MARRIED. SO THIS WAS A REALLY GREAT STORY
18	THAT I'VE ACTUALLY BEEN WORKING ON UPDATING AS I
19	KNOW JAKE PERSONALLY. AND IT'S A GREAT WAY OF
20	SHOWING OUR READERS THE IMPACT OF BEING INVOLVED IN
21	A CLINICAL TRIAL AND REALLY IMPROVING AND GETTING TO
22	HIS ULTIMATE GOAL.
23	ANOTHER STORY, IF YOU GO TO THE NEXT PAGE,
24	IS MORE FOCUSED ON THE RARE DISEASES. THIS IS
25	CONNOR'S STORY WHO WAS DIAGNOSED WITH THE SCN2A GENE

1	AND HAS BEEN IN AN ONGOING INVESTIGATIONAL GENE
2	THERAPY AND HAS SEEN A GREAT DEAL OF IMPROVEMENT.
3	AS YOU CAN SEE, HE HAS BEGUN WRITING ON A KEYBOARD,
4	SLEEPING BETTER. HE HAS GAINED A LOT OF MOBILITY.
5	AGAIN, ANOTHER TESTAMENT TO THE POWER OF THE WORK
6	THAT WE FUND.
7	AND WHAT WAS COOL ABOUT THIS PARTICULAR
8	STORY THAT WE SHARED WAS THAT WE HAD A VIDEO
9	INTERVIEW WITH THE PRINCIPAL INVESTIGATOR WHO IS
10	OLIVIA KIM-MCMANUS. AND SHE DID THIS REALLY GREAT
11	INTERVIEW FOR US. IT'S SOMETHING THAT WE'RE HOPING
12	TO UTILIZE MORE, BEING ABLE TO INTERVIEW NOT ONLY
13	THE PI'S, BUT ALSO SHARING THE PATIENT'S PERSPECTIVE
14	TO GIVE PEOPLE THAT REALLY IN-DEPTH UNDERSTANDING OF
15	THE WORK THAT WE DO HERE AT THE AGENCY.
16	MS. DURON: KATIE.
17	MS. SHARIFY: YES.
18	MS. DURON: SORRY. I TRIED TO PUT MY HAND
19	UP.
20	SO IS THERE SOMETHING PEOPLE CLICK ON AND
21	THERE'S A STORY BEHIND THIS, OR THIS IS WHAT WE GET?
22	MS. SHARIFY: ON THE PRESENTATION YOU'RE
23	SAYING?
24	MS. DURON: NO. NO. ON CONNOR'S
25	STORY.

1	MS. SHARIFY: THIS IS AN EXCERPT FROM THE
2	ONE THAT IS POSTED.
3	MS. DURON: SO WHAT I WANT TO SAY IS THAT
4	YOU SAY A RARE MUTATION IN THE SCN2A GENE. I HAVE
5	NO CLUE WHAT THAT DOES OR WHAT IT IS. AND I THINK A
6	LOT OF READERS WOULD NOT KNOW EITHER. SO I THINK
7	YOU NEED FIRST TO TELL THEM HOW THAT IMPACTED HIS
8	LIFE OR HOW IT SHAPED HIS LIFE SO THAT THEY KNOW
9	WHAT THE IMPROVEMENTS LOOK LIKE FROM WHERE HE WAS
10	AT.
11	SO MAYBE IT'S A BIG STORY, BUT I THINK YOU
12	ALWAYS NEED TO EXPLAIN THE PARTICULAR RARE DISEASE
13	BECAUSE MOST OF US AREN'T FAMILIAR WITH IT.
14	MS. SHARIFY: OF COURSE. THAT'S THE WAY
15	THAT WE ALWAYS TRY TO DO ESPECIALLY SOMETIMES WE
16	POST A PART OF THE PRESS RELEASES OF THE RESEARCH
17	THAT WE'RE FUNDING. AND THAT'S WHERE WE REALLY TRY
18	TO HELP PEOPLE UNDERSTAND WHAT THE RESEARCH, WHAT
19	THE SCIENCE IS ABOUT BEFORE WE GET INTO THE IMPACTS
20	FOR THE PATIENT AFTER A PRESENTATION. BUT THANK YOU
21	FOR THAT, YSABEL.
22	MS. TEMPLE-PERRY: JUST BEFORE WE MOVE ON,
23	THESE WERE JUST A COUPLE OF STORIES THAT WE'VE
24	HIGHLIGHTED, BUT WE HAVE A NUMBER OF STORIES ACROSS
25	OUR BLOG AND SOCIAL MEDIA WITH PATIENTS, TRAINEES,

1	AND RESEARCHERS. SO AS KATIE MENTIONED, REALLY
2	UTILIZING THE USE OF STORYTELLING TO ILLUSTRATE SOME
3	OF THESE REALLY IMPORTANT FACETS OF CIRM AND WHAT WE
4	DO AND WHAT WE ENGAGE WITH.
5	ON THE NEXT SLIDE, AND SO IN AN ONGOING
6	EFFORT TO INFORM AND EDUCATE THE PUBLIC, WE POSTED A
7	RECENT WEBINAR ON "ADVANCES IN EYE DISEASE AND
8	REGENERATIVE MEDICINE," WHICH GARNERED A LOT OF
9	STRONG ENGAGEMENT. AND JACQUELINE, WHO, AGAIN, IS
10	OUR SENIOR OUTREACH ADVISOR, WAS REALLY INSTRUMENTAL
11	IN ORGANIZING THIS EFFORT. SO I'M GOING TO INVITE
12	HER TO SPEAK A LITTLE BIT ON THIS INITIATIVE.
13	MS. HANTGAN: THANK YOU SO MUCH. GOOD
14	AFTERNOON, EVERYONE. MY NAME IS JACQUELINE AS
15	MENTIONED, AND I AM BASED IN THE LOS ANGELES AREA.
16	THIS WAS REALLY AN EXCITING EFFORT,
17	ENDEAVOR AND WELL RECEIVED, AS YOU CAN SEE BY SOME
18	OF THE NUMBERS. THIS WAS THE FIRST OF HOPEFULLY
19	MANY THAT WE'LL LOOK TO EXPLORE AND DEVELOP OVER THE
20	NEXT YEAR AND ONGOING.
21	THE NAME OF THIS WAS "EXPLORING ADVANCES
22	IN EYE DISEASE AND REGENERATIVE MEDICINE." WE HAD
23	DR. DAVID LIAO AND DR. PABLO AVALOS WHO ALSO PABLO
24	RUNS THE ALPHA CLINIC PROGRAM AT CEDARS. AND THEY
25	WERE OUR CLINICIANS AND EXPERTS IN THE FIELD. TWO

1	PATIENT ADVOCATES. KRISTEN MCDONALD I THINK SOME OF
2	YOU MIGHT BE FAMILIAR WITH. KRISTEN, OF COURSE, AND
3	VERONICA AS WELL. THEY WERE BOTH IN EARLY TRIALS AT
4	DIFFERENT TIMES. AND THEY SHARED THEIR EXPERIENCE
5	BEAUTIFULLY. AND DR. ABLA, OF COURSE, INTRODUCED
6	THE WEBINAR. AND IT WAS REALLY EXCELLENT, AND IT'S
7	A PUBLIC SERVICE THAT WE SHOULD CONTINUE TO EXPLORE
8	AND DEVELOP AND GIVE BACK TO NOT JUST CALIFORNIANS,
9	BUT PEOPLE HAVE ACCESS TO PARTICIPATE WORLDWIDE.
10	THE FEW COMMENTS THAT WE RECEIVED BACK
11	WE DIDN'T ASK FOR THEM. IT'S SOMETHING WE CAN
12	CONSIDER IN THE FUTURE JUST IN TERMS OF A
13	FOLLOW-UP WERE VERY WELL RECEIVED. AND PEOPLE
14	JUST APPRECIATED THE EFFORTS, BUT ALSO THE ABILITY
15	TO EXPLORE AND TALK ABOUT SCIENCE, EVERY PERSON, FOR
16	A LAYPERSON WHO IS NOT NECESSARILY A SCIENTIST, BUT
17	THAT'S AFFECTED IN ONE WAY, SHAPE, OR THE OTHER.
18	SO THANK YOU FOR THE OPPORTUNITY TO TALK
19	ABOUT THE WEBINAR AND BE HERE WITH YOU TODAY.
20	MS. DURON: JACQUELINE.
21	MS. HANTGAN: YES, YSABEL.
22	MS. DURON: ONE OF THE THINGS I ALWAYS
23	LIKE TO SEE IS WHEN YOU PUT 135 REGISTRANTS, I'D
24	LIKE TO KNOW IF YOU GOT A DIVERSE AUDIENCE. BECAUSE
25	I THINK THAT'S VERY CRUCIAL IN WHETHER OUR OUTREACH

1	IS WORKING TO THOSE DIVERSE AUDIENCES OR WHY WE
2	CAN'T GET THEM. I THINK CEDARS-SINAI DOES HAVE A
3	LITTLE BIT OF DIVERSITY GOING ON OVER THERE NOW.
4	MS. HANTGAN: THAT'S A GREAT QUESTION.
5	AND IT'S HARD TO KNOW. WHEN WE DID THE FIRST
6	WHEN WE DID THE REGISTRATION, WE DIDN'T ASK FOR
7	SPECIFIC QUESTIONS LIKE THAT. IN OUR FOLLOW-UP WE
8	DID TALK ABOUT GOING FORWARD INCLUDING A FOLLOW-UP
9	SURVEY, BUT WE COULD EXPLORE TOGETHER WITH THE COMMS
10	TEAM. I'M HAPPY TO TALK WITH YOU SEPARATELY AND
11	ANYBODY ELSE ABOUT HOW WE SENSITIVELY AND
12	THOUGHTFULLY HOW WE CAN GO ABOUT GAINING THAT
13	INFORMATION IN THE RIGHT WAY.
14	SO IT'S HARD TO KNOW. WE FIELD PHONE
1 4	
15	CALLS AND OUTREACH EFFORTS FROM PATIENTS AROUND THE
15	CALLS AND OUTREACH EFFORTS FROM PATIENTS AROUND THE
15 16	CALLS AND OUTREACH EFFORTS FROM PATIENTS AROUND THE WORLD. ALL THOSE PEOPLE AT LEAST HAD ACCESS TO THIS
15 16 17	CALLS AND OUTREACH EFFORTS FROM PATIENTS AROUND THE WORLD. ALL THOSE PEOPLE AT LEAST HAD ACCESS TO THIS INVITATION AS LONG AS WE HAD AN EMAIL ADDRESS FROM
15 16 17 18	CALLS AND OUTREACH EFFORTS FROM PATIENTS AROUND THE WORLD. ALL THOSE PEOPLE AT LEAST HAD ACCESS TO THIS INVITATION AS LONG AS WE HAD AN EMAIL ADDRESS FROM THEM. AS YOU KNOW, A LOT OF PEOPLE JOIN EVEN
15 16 17 18 19	CALLS AND OUTREACH EFFORTS FROM PATIENTS AROUND THE WORLD. ALL THOSE PEOPLE AT LEAST HAD ACCESS TO THIS INVITATION AS LONG AS WE HAD AN EMAIL ADDRESS FROM THEM. AS YOU KNOW, A LOT OF PEOPLE JOIN EVEN THOUGH A LOT OF THESE PEOPLE REGISTERED DIDN'T MEAN
15 16 17 18 19 20	CALLS AND OUTREACH EFFORTS FROM PATIENTS AROUND THE WORLD. ALL THOSE PEOPLE AT LEAST HAD ACCESS TO THIS INVITATION AS LONG AS WE HAD AN EMAIL ADDRESS FROM THEM. AS YOU KNOW, A LOT OF PEOPLE JOIN EVEN THOUGH A LOT OF THESE PEOPLE REGISTERED DIDN'T MEAN EVERYONE ATTENDED. AND A LOT OF PEOPLE WHO DID
15 16 17 18 19 20 21	CALLS AND OUTREACH EFFORTS FROM PATIENTS AROUND THE WORLD. ALL THOSE PEOPLE AT LEAST HAD ACCESS TO THIS INVITATION AS LONG AS WE HAD AN EMAIL ADDRESS FROM THEM. AS YOU KNOW, A LOT OF PEOPLE JOIN EVEN THOUGH A LOT OF THESE PEOPLE REGISTERED DIDN'T MEAN EVERYONE ATTENDED. AND A LOT OF PEOPLE WHO DID ATTEND DIDN'T NECESSARILY HAVE THEIR CAMERAS ON. SO
15 16 17 18 19 20 21 22	CALLS AND OUTREACH EFFORTS FROM PATIENTS AROUND THE WORLD. ALL THOSE PEOPLE AT LEAST HAD ACCESS TO THIS INVITATION AS LONG AS WE HAD AN EMAIL ADDRESS FROM THEM. AS YOU KNOW, A LOT OF PEOPLE JOIN EVEN THOUGH A LOT OF THESE PEOPLE REGISTERED DIDN'T MEAN EVERYONE ATTENDED. AND A LOT OF PEOPLE WHO DID ATTEND DIDN'T NECESSARILY HAVE THEIR CAMERAS ON. SO AS IT WAS A WEBINAR, IT WAS ACTUALLY IT WAS A
15 16 17 18 19 20 21 22 23	CALLS AND OUTREACH EFFORTS FROM PATIENTS AROUND THE WORLD. ALL THOSE PEOPLE AT LEAST HAD ACCESS TO THIS INVITATION AS LONG AS WE HAD AN EMAIL ADDRESS FROM THEM. AS YOU KNOW, A LOT OF PEOPLE JOIN EVEN THOUGH A LOT OF THESE PEOPLE REGISTERED DIDN'T MEAN EVERYONE ATTENDED. AND A LOT OF PEOPLE WHO DID ATTEND DIDN'T NECESSARILY HAVE THEIR CAMERAS ON. SO AS IT WAS A WEBINAR, IT WAS ACTUALLY IT WAS A WEBINAR. SO THAT WOULDN'T BE IT WAS ONE FACING.

1	OUT WHERE THESE PEOPLE ARE COMING FROM AND HOW THEY
2	LEARN ABOUT THE WEBINAR AND SO FORTH.
3	MR. CORTEZ: JACQUELINE, JUST VERY
4	QUICKLY. THANK YOU FOR SHARING THAT. I CAN CHIME
5	IN ON THAT. ASIDE FROM PROMOTING THIS WEBINAR
6	WIDELY ON OUR SOCIAL MEDIA CHANNELS, THROUGH OUR
7	EMAILS TO OUR OWN AUDIENCES, WE DID ALSO EXTEND
8	INVITES TO COMMUNITIES ON FACEBOOK. WE ALSO REACHED
9	OUT TO FACEBOOK GROUPS FOCUSED ON VISION LOSS OR
10	RETINITIS PIGMENTOSA. I THINK THAT WAS ONE OF THE
11	REASONS WHY WE WERE ABLE TO GET A HIGH NUMBER OF
12	REGISTRANTS FOR THE I THINK IT WAS ABOUT TWO
13	WEEKS THAT WE WERE PROMOTING THIS. SO EVEN THOUGH
14	WE INVITED THE GENERAL PUBLIC, WE DID ALSO EMPHASIZE
15	ENCOURAGING PATIENTS WHO EITHER WERE PATIENT
16	ADVOCATES WITH VISION LOSS OR WHO WERE LIVING WITH
17	CONDITIONS LIKE RETINITIS PIGMENTOSA OR MACULAR
18	DEGENERATION.
19	SO I DID WANT TO RECOGNIZE THAT WE DID DO
20	SOME OUTREACH TO SOME OF THOSE COMMUNITIES. AND IN
21	ADDITION TO THAT, WE WORKED WITH KRISTEN MCDONALD,
22	ONE OF THE PATIENTS THERE, TO PROMOTE THE EVENT TO
23	HER OWN COMMUNITY, WHICH I BELIEVE WAS THE
24	FOUNDATION FIGHTING BLINDNESS, TO EXTEND AN INVITE
25	AS WELL.

1	MS. HANTGAN: IN ADDITION TO THE BRAILE
2	INSTITUTE, WHICH WAS DIRECT RELATED TO THE COMMUNITY
3	THAT KRISTEN IS INVOLVED IN. SO WE'LL DO MORE OF
4	THAT IN THIS KIND OF MUSHROOM EXPERIENCE,
5	OPPORTUNITY TO WORK WITHIN PATIENT ADVOCACY
6	ORGANIZATIONS AS WELL.
7	MS. DURON: SO, ESTEBAN, ONE FOLLOW-UP.
8	DID YOU ALSO IN REACHING OUT BY SOCIAL MEDIA AND ALL
9	OF THOSE GROUPS, DID YOU GIVE SPECIFIC DATA ABOUT
10	SOME OF THE DIFFERENT GROUPS AND HOW THEY'RE
11	IMPACTED SO THAT THEY KNOW IT MEANS THEM TOO?
12	BECAUSE SOMETIMES IT'S A VERY GENERAL MESSAGE.
13	PEOPLE DON'T KNOW THAT MAYBE THEY SHOULD FIND OUT
14	ABOUT THIS IF THEY LEARN. THIS IS HAPPENING IN
15	YOUR 5 PERCENT OF YOUR COMMUNITY WAS IMPACTED BY
16	THIS. AND SO I THINK IT'S REALLY IMPORTANT TO HAVE
17	A LITTLE BIT OF DATA IN THOSE MESSAGES.
18	MR. CORTEZ: YEAH. YEAH. ABSOLUTELY. I
19	DO WANT TO RECOGNIZE THAT WE DID INCLUDE SOME DATA
20	ON THE CIRM SITE AROUND HOW MUCH WE FUNDED IN THIS
21	AREA. AND THIS WAS JUST A REALLY GREAT
22	COLLABORATIVE EFFORT BECAUSE YOU CAN SEE ON THE
23	SCREENSHOT HERE THE PARTICIPANTS THAT ABLA
24	PARTICIPATED, WHO WAS REALLY HELPFUL IN EVEN, AGAIN,
25	HIGHLIGHTING SOME OF THE RESEARCH PROJECTS THAT WE
	10

1	FUNDED. I DON'T HAVE THE NUMBER AROUND HOW MUCH WE
2	FUNDED IN THIS AREA AT THE MOMENT, BUT WE DID MAKE
3	SURE TO INCLUDE SOME OF THOSE KEY MESSAGES IN SOME
4	OF OUR OUTREACH.
5	MS. DURON: THAT'S NOT WHAT I'M TALKING
6	ABOUT. I'M TALKING ABOUT PATIENTS THEMSELVES AND
7	WHICH COMMUNITIES THEY COME FROM AND, THEREFORE, HOW
8	THEY'RE IMPACTED. AND, THEREFORE, THEY MIGHT WANT
9	TO PARTICIPATE. SO IF THIS IS KIND OF A DISEASE AND
10	AN ISSUE THAT MIGHT IMPACT 5 PERCENT OF THE BLACK
11	COMMUNITY OR 7 PERCENT OF THE LATINO COMMUNITY OR 10
12	PERCENT OF THE ASIAN COMMUNITY, I THINK THOSE LITTLE
13	DATA POINTS ARE REALLY CRITICAL FOR SOMEONE TO SAY,
14	I DIDN'T KNOW THAT WAS A PROBLEM IN MY COMMUNITY.
15	MAYBE WE SHOULD LEARN MORE. THAT'S TO ME WHAT THAT
16	SOCIAL MEDIA OUTREACH IS ABOUT.
17	MR. CORTEZ: OKAY. THANK YOU.
18	CHAIRPERSON BONNEVILLE: REALLY QUICKLY,
19	I'M SO HAPPY TO SEE THESE COME BACK INTO THE FOLD.
20	THIS USED TO BE SOMETHING WE WOULD DO YEARS AGO
21	WHERE WE WOULD HAVE FACEBOOK BACK THEN IT WAS
22	FACEBOOK LIVE, AND I'M NOT SURE IF THAT'S EVEN THE
23	RIGHT FORM ANYMORE. SO THAT'S SOMETHING ELSE TO
24	CONSIDER, BUT THESE WERE REALLY POPULAR.
25	OUR INTERNAL TEAM LOVED IT, THE
	17

1	RESEARCHERS LOVED IT, AND THE PATIENT ADVOCATES
2	LOVED IT. SO I'M REALLY HAPPY TO SEE THIS COME
3	BACK. SO THANK YOU.
4	MS. HANTGAN: THANK YOU. AND I WILL SAY
5	PRIOR TO THAT, IN THE EARLY, EARLY DAYS, WE HAD THE
6	SPOTLIGHT ON DISEASES IN THE EARLY DAYS OF THE
7	CREATION. SO THANK YOU.
8	MS. TEMPLE-PERRY: THANK YOU. AND THANK
9	YOU, YSABEL, FOR YOUR COMMENTS. WE'LL DEFINITELY
10	INCORPORATE THAT FEEDBACK INTO PLANNING THESE
11	WEBINARS MOVING FORWARD. AND THANK YOU, JACQUELINE,
12	ALSO FOR PROVIDING AN OVERVIEW OF THAT GREAT, GREAT
13	WEBINAR.
14	SO NEXT I'D LIKE TO TOUCH ON THE ROLE OF
15	OUR MEDIA AND OUR COMMUNICATION EFFORTS. AND JUST
16	SO I'M BEING VERY CLEAR, EARNED MEDIA BASICALLY
17	REFERS TO SORT OF EXPOSURE OR COVERAGE THAT WE
18	RECEIVE FROM OTHER ORGANIZATIONS, OTHER MEDIA
19	OUTLETS OUTSIDE OF CIRM. AND SO THIS COULD INCLUDE
20	NEWSPAPER ARTICLES, NEWSLETTER FEATURES, BLOGS,
21	PODCASTS, ET CETERA, ALL THE VARIOUS TYPES OF MEDIA
22	THAT ARE OUT THERE.
23	AND SO OVER THE PAST YEAR, WE HAVE
24	INCREASED OUR EARNED MEDIA COVERAGE BY ABOUT 32
25	PERCENT. OVER THE PAST QUARTER, WE'VE SEEN A

1	SIGNIFICANT UPTICK IN THAT WHERE WE'VE HAD COVERAGE
2	IN VARIOUS REGIONS, SUCH AS SOUTHERN CALIFORNIA,
3	EVEN IN FRESNO AND CENTRAL CALIFORNIA. YOU CAN SEE
4	HERE IN THE NEXT COUPLE OF SLIDES WE HAVE A NUMBER
5	OF EXAMPLES ACTUALLY GO BACK ONE SECOND OF OUR
6	EARNED MEDIA COVERAGE, INCLUDING FEATURING OUR
7	FUNDED RESEARCH, PATIENT STORIES. J.T. WAS VERY
8	POPULAR. AND ACTUALLY WE HAD THOSE PHOTOS TAKEN TO
9	MAKE SURE THAT HE HAD A NICE SHOT TO GO WITH THIS.
10	THESE ARE JUST, AGAIN, A COUPLE OF
11	EXAMPLES OF SOME OF THE MEDIA COVERAGE THAT WE
12	RECEIVED OVER THIS PAST QUARTER IF YOU KEEP
13	GOING THINGS SUCH AS RESEARCH, TALKING ABOUT OUR
14	MANUFACTURING NETWORK, A LOT OF UPTICK AND COVERAGE
15	OF OUR AWARDS AROUND OUR EDUCATION AND TRAINING
16	PROGRAMS. WE HAD A REALLY NICE FEATURE IN THE LOS
17	ANGELES TIMES TALKING ABOUT SORT OF THE HURDLES OF
18	THE RARE COMMUNITY AND HOW CIRM IS REALLY FOCUSED ON
19	MAKING SURE THAT WHAT WE FUND IS GOING TO CONTINUE
20	TO INCLUDE THE PRIORITIES FOR THE RARE DISEASE
21	COMMUNITY.
22	THERE WAS A NICE PATIENT STORY THAT RAN ON
23	ABC IN FRESNO, CENTRAL CALIFORNIA. WE HAD A REALLY
24	NICE SHOUT-OUT THERE. AND, AGAIN, THIS WAS A LOT OF
25	COLLABORATIVE EFFORTS WITH OUR MEDIA PARTNERS TO

1	PULL THIS TOGETHER.
2	AND SO I WILL JUST SAY WE ATTRIBUTE THESE
3	INCREASES TO A FEW KEY REASONS. ONE, WE HAVE OVER
4	THE PAST FEW MONTHS REALLY FOCUSED ON ESTABLISHING A
5	PROTOCOL FOR OUR COMMUNICATIONS TEAM. WE RELEASED
6	PRESS RELEASES REGULARLY. IN ADDITION TO THAT,
7	WHICH IS REALLY, REALLY CRUCIAL TO EARNED MEDIA, IS
8	THAT WE'VE INCREASED OUR OWN MEDIA. SO THAT'S
9	HIGHLIGHTING OUR PROGRAMS, TALKING ABOUT OUR KEY
10	ACHIEVEMENTS ACROSS ALL OF OUR SOCIAL NETWORK, OUR
11	BLOGS, PUTTING INFORMATION OUT THERE. THE MORE
12	THAT'S PUT OUT THERE, THE MORE PEOPLE ARE GOING TO
13	RECOGNIZE OUR EFFORTS.
14	TWO, IN ADDITION TO THAT, WE REALLY
14 15	TWO, IN ADDITION TO THAT, WE REALLY PRIORITIZED OUR RELATIONSHIP BUILDING WITH
15	PRIORITIZED OUR RELATIONSHIP BUILDING WITH
15 16	PRIORITIZED OUR RELATIONSHIP BUILDING WITH COMMUNICATION TEAMS. SAY, FOR EXAMPLE,
15 16 17	PRIORITIZED OUR RELATIONSHIP BUILDING WITH COMMUNICATION TEAMS. SAY, FOR EXAMPLE, COMMUNICATIONS TEAMS THAT ARE AT A LOT OF OUR ALPHA
15 16 17 18	PRIORITIZED OUR RELATIONSHIP BUILDING WITH COMMUNICATION TEAMS. SAY, FOR EXAMPLE, COMMUNICATIONS TEAMS THAT ARE AT A LOT OF OUR ALPHA CLINIC NETWORKS AS WELL AS DEVELOPING KEY
15 16 17 18 19	PRIORITIZED OUR RELATIONSHIP BUILDING WITH COMMUNICATION TEAMS. SAY, FOR EXAMPLE, COMMUNICATIONS TEAMS THAT ARE AT A LOT OF OUR ALPHA CLINIC NETWORKS AS WELL AS DEVELOPING KEY RELATIONSHIPS WITH RESEARCHERS AND PI'S. AND SO
15 16 17 18 19	PRIORITIZED OUR RELATIONSHIP BUILDING WITH COMMUNICATION TEAMS. SAY, FOR EXAMPLE, COMMUNICATIONS TEAMS THAT ARE AT A LOT OF OUR ALPHA CLINIC NETWORKS AS WELL AS DEVELOPING KEY RELATIONSHIPS WITH RESEARCHERS AND PI'S. AND SO THEY HAVE KEPT US IN THE LOOP, AND WE REALLY WORK
15 16 17 18 19 20	PRIORITIZED OUR RELATIONSHIP BUILDING WITH COMMUNICATION TEAMS. SAY, FOR EXAMPLE, COMMUNICATIONS TEAMS THAT ARE AT A LOT OF OUR ALPHA CLINIC NETWORKS AS WELL AS DEVELOPING KEY RELATIONSHIPS WITH RESEARCHERS AND PI'S. AND SO THEY HAVE KEPT US IN THE LOOP, AND WE REALLY WORK COLLABORATIVELY TO ENHANCE THE MEDIA THAT COMES OUT
15 16 17 18 19 20 21	PRIORITIZED OUR RELATIONSHIP BUILDING WITH COMMUNICATION TEAMS. SAY, FOR EXAMPLE, COMMUNICATIONS TEAMS THAT ARE AT A LOT OF OUR ALPHA CLINIC NETWORKS AS WELL AS DEVELOPING KEY RELATIONSHIPS WITH RESEARCHERS AND PI'S. AND SO THEY HAVE KEPT US IN THE LOOP, AND WE REALLY WORK COLLABORATIVELY TO ENHANCE THE MEDIA THAT COMES OUT OF THIS.
15 16 17 18 19 20 21 22	PRIORITIZED OUR RELATIONSHIP BUILDING WITH COMMUNICATION TEAMS. SAY, FOR EXAMPLE, COMMUNICATIONS TEAMS THAT ARE AT A LOT OF OUR ALPHA CLINIC NETWORKS AS WELL AS DEVELOPING KEY RELATIONSHIPS WITH RESEARCHERS AND PI'S. AND SO THEY HAVE KEPT US IN THE LOOP, AND WE REALLY WORK COLLABORATIVELY TO ENHANCE THE MEDIA THAT COMES OUT OF THIS. AND WE'VE ALSO ESTABLISHED RELATIONSHIPS

1	HAPPENED. MAYBE THEY DON'T HAVE SOMETHING RIGHT NOW
2	FOR US; BUT BY REGULARLY ENGAGING, THIS IS REALLY,
3	REALLY CRUCIAL TO HIGHLIGHTING A LOT OF OUR MEDIA
4	AND MAKING SURE THAT WE'RE DEVELOPING ENOUGH
5	COVERAGE IN WHAT WE'RE DOING.
6	AND SO I WOULD SAY THAT THE THIRD POINT IS
7	THAT WE HAVE INVESTED IN OUR MEDIA ANALYTICS AND
8	MONITORING TOOLS. SO FOR CONTEXT AND CLARIFICATION,
9	RIGHT NOW A LOT OF OUR MEDIA LIST IS BASICALLY
10	RUN THROUGH MAILCHIMP WHICH IS BASICALLY STATIC. WE
11	RENEGOTIATED A CONTRACT WITH MELTWATER, WHICH IS OUR
12	MEDIA MONITORING TOOL. WE HAVE NOW ENHANCED
13	CAPABILITIES SUCH AS PITCHING TOOLS. AND THAT IS
14	REALLY UTILIZING REAL-TIME INSIGHTS TO KNOW WHO ARE
15	THE KEY REPORTERS, WHAT ARE THEIR NEEDS, WHAT ARE
16	THEY COVERING NOW. WHEREAS, OUR STATIC LIST, WE
17	DIDN'T HAVE THAT OPPORTUNITY IF SOMEBODY LEFT A
18	PUBLICATION OR THEIR BEAT CHANGED, WE HAD NO IDEA.
19	WE DIDN'T HAVE THOSE INSIGHTS. AND SO BY NOW
20	RENEGOTIATING OUR CONTRACT, INCREASING OUR
21	CAPABILITIES, WE WILL REALLY BE ABLE TO CONTINUE TO
22	PITCH THE RIGHT MATERIALS TO THE RIGHT REPORTERS.
23	AND SO, AGAIN, I THINK WE'LL CONTINUE TO
24	MOVE THIS FORWARD. THERE'S ANOTHER EFFORT
25	INTERNALLY, IT'S NOT YET READY FOR PRIME TIME, BUT

1	REALLY FOCUSING ON MAKING SURE THAT PEOPLE ARE
2	INCLUDING US, FOLKS WHO ARE RECEIVING CIRM-FUNDED
3	RESEARCH, IN THEIR PRESS RELEASES. AND WE ARE
4	THINKING THROUGH A STRATEGY INTERNALLY TO MAKE THAT
5	A REQUIREMENT. NEXT SLIDE.
6	I'M GOING TO TRANSITION ON, AND I'M GOING
7	TO LET ESTEBAN PROVIDE AN OVERVIEW OF A COUPLE OF
8	CONFERENCES WE ATTENDED RECENTLY.
9	MR. CORTEZ: ABSOLUTELY. AND THEN JUST
10	BEFORE I GET INTO THIS, I JUST WANTED TO RECOGNIZE
11	THAT ON THE PREVIOUS SLIDE ABC 30 IS THE NEWS
12	CHANNEL THAT I GREW UP WATCHING IN CENTRAL
13	CALIFORNIA. SO IT WAS REALLY GREAT TO SEE A PATIENT
14	STORY FROM CENTRAL CALIFORNIA. AND I'VE BEEN ABLE
15	TO CONNECT UP WITH A MOM WHO (INAUDIBLE) UPCOMING
16	TREATMENT AT UCLA. SO WE LOOK FORWARD TO SHARING
17	MORE ABOUT THAT.
18	IF YOU GO TO THE NEXT SLIDE, CHRISTINA, I
19	WANT TO RECOGNIZE THAT, IN ADDITION TO SOME OF THAT
20	COLLABORATION THAT KOREN JUST HIGHLIGHTED, WE SPENT
21	SOME TIME THIS SUMMER WORKING WITH VARIOUS TEAMS TO
22	SUPPORT THE SPARK AND TRAINEE CONFERENCES AT UC
23	RIVERSIDE AND USC. BUT BEFORE I GET INTO THAT, I
24	DID REALLY WANT TO RECOGNIZE AND HIGHLIGHT THE HARD
25	WORK THAT DAISY SIN AND KELLY SHEPARD PUT IN TO

1	ORGANIZING THESE CONFERENCES AND MAKING THEM A HUGE
2	SUCCESS. SO I WANTED TO DO THAT BEFORE I GET INTO
3	SOME OF THE WORK THAT COMMS DID FOR THESE.
4	BUT REALLY WHAT WE DID IS WE PROVIDED
5	MARKETING SUPPORT FOR BOTH CONFERENCES, AND THAT
6	INCLUDED BRANDING, MESSAGING SUPPORT. WE ALSO
7	CREATED SOCIAL MEDIA TOOLKITS FOR THE ENTRANTS AND
8	TRAINEES TO ENGAGE ON SOCIAL MEDIA. FOR THE SPARK
9	CONFERENCE, WE WORKED CLOSELY WITH THE UC RIVERSIDE
10	EVENT PLANNERS AND THE MEDIA TEAMS TO AMPLIFY
11	COVERAGE OF THE EVENT. AND AS YOU CAN SEE HERE,
12	SOME OF THESE SCREENSHOTS, WE, OF COURSE, GATHERED
13	SOME CONTENT. WE MADE SURE THAT WE ASKED SOME OF
14	THE STUDENTS ABOUT THEIR PERSPECTIVES. HOW WOULD
15	THEY TALK TO THEIR FAMILY MEMBERS ABOUT REGENERATIVE
16	MEDICINE? WE ALSO WORKED WITH THE UC RIVERSIDE TEAM
17	TO THE COLLEGE OF ENGINEERING TO ISSUE A JOINT
18	RELEASE. IT WAS REALLY IN DEPTH AND REALLY
19	HIGHLIGHTED CIRM'S INVOLVEMENT IN MAKING THIS
20	CONFERENCE HAPPEN AND FUNDING SOME OF THESE PROGRAMS
21	ACROSS THE STATE. SO THAT WAS A REALLY BIG SUCCESS.
22	IF YOU GO TO THE NEXT SLIDE, CHRISTINA.
23	WE'VE ALSO OFFERED VERY SIMILAR SUPPORT TO THE
24	TRAINEE CONFERENCE, AGAIN COLLABORATING WITH KELLY,
25	DAISY, AND THE USC TEAM TO AMPLIFY THIS EVENT. I'D,

1	AGAIN, REALLY LIKE TO HIGHLIGHT THAT WE BOOSTED OUR
2	SOCIAL MEDIA OUTREACH FOR BOTH CONFERENCES THIS
3	YEAR, WHICH CHRISTINA WILL HIGHLIGHT BRIEFLY.
4	MS. SMITH: SO BECAUSE OF THE HASHTAG CIRM
5	TRAINING CONFERENCE, WE SAW THAT THAT HASHTAG
6	REACHED OVER 17,000 UNIQUE ACCOUNTS ACROSS TWITTER
7	AND INSTAGRAM SORRY, X AND INSTAGRAM. AND THEN
8	WE ALSO SAW THAT ON BOTH PLATFORMS CIRM WAS
9	MENTIONED OR TAGGED OVER 200 TIMES, WHICH IS WITHIN
10	A TWO-WEEK PERIOD, WHICH IS PRETTY GOOD. AND WE
11	ALSO NOTICED THAT WITHIN JUST A WEEK OVER 50 UNIQUE
12	ACCOUNTS USED, NOT REACHED, BUT USED THE HASHTAG,
13	BOTH HASHTAGS, CIRM TRAINEE CONFERENCE AND
14	CIRMSPARKLAB, WHICH IS PRETTY GOOD SINCE WE ONLY HAD
15	A COUPLE WEEKS TO REALLY PUSH IT OUT THERE.
16	MS. DURON: CAN I ASK A QUESTION, MARIA
17	CHAIRPERSON BONNEVILLE: YES, PLEASE DO.
18	MS. DURON: ACTUALLY OF YOU? I'M JUST
19	WONDERING. I KNOW X IS VERY POPLAR, BUT I'M
20	WONDERING IF, GIVEN ITS INFLAMMATORY MESSAGING AND
21	THE LEADERSHIP, I'M WONDERING IF THIS MIGHT SEND A
22	DIFFERENT IMPRESSION OF CIRM THAN WE WANT IT TO BE,
23	OUR VALUES, OUR BELIEFS. MY AGENCY LEFT X BECAUSE
24	WE DID NOT WANT TO BE ASSOCIATED OR AFFILIATED WITH
25	ALL OF THE MIS- AND DISINFORMATION THAT WAS GOING ON
	2.4

1	THERE. SO I'M JUST ASKING IF CIRM BROADLY, THE
2	BOARD OR LEADERSHIP, HAS RECONSIDERED WHETHER OR NOT
3	WE WANT TO STAY ON X OR WE WANT TO WE HAVE A
4	MESSAGE THAT DESCRIBES WHY WE'RE THERE? OR I DON'T
5	KNOW. I'M JUST CONCERNED ABOUT THAT, AND I DON'T
6	KNOW IF WE DISCUSSED IT YET.
7	CHAIRPERSON BONNEVILLE: THANK YU, YSABEL.
8	ACTUALLY A COUPLE OF MONTHS AGO I DID TALK TO
9	CHRISTINA ABOUT THIS AND EXPRESSED SIMILARLY. IS
10	THIS SOMETHING WE SHOULD BE CONSIDERING? AND IN
11	TALKING TO CHRISTINA AND TALKING TO SOME OF THE
12	OTHER SCIENCE OFFICERS IN THE ORGANIZATION, X IS
13	STILL REALLY A PLATFORM THAT A LOT OF MAJOR SCIENCE
14	POLICY IS DISCUSSED, SCIENCE NEWS COMES OUT, AND
15	THERE'S A LOT OF EXCHANGE OF INFORMATION AND IDEAS
16	THAT COMES OUT OF THAT PLATFORM.
17	SO I THINK WE FELT THAT LEAVING THAT
18	PLATFORM WOULD ACTUALLY PROBABLY NOT BE GREAT FOR US
19	IN UNDERSTANDING SORT OF WHAT IS GOING ON OUT THERE
20	AND WHAT THE SCIENCE WORLD AND THE RESEARCH WORLD IS
21	SAYING.
22	NOW, PERHAPS PROVIDING A COMMENT ABOUT WHY
23	WE ARE AND MAKING SURE THAT PEOPLE UNDERSTAND THAT
24	WE DO WANT TO STAY INVOLVED IN WHAT IS HAPPENING
25	DESPITE PERHAPS THE AFFILIATIONS OF SOME OF THEIR

1	OWNERSHIP AND LEADERSHIP. SO THAT'S I LEAVE THAT
2	UP TO THE COMMUNICATION TEAM TO SORT OF FIGURE OUT
3	AND MAYBE COME BACK TO US WITH A THOUGHT ON THAT.
4	MS. DURON: COULD I ASK CHRISTINE OR LINDA
5	OR ELENA FLOWERS OR LAURA, ANYBODY HAVE OTHER
6	OPINIONS ABOUT THIS OR CONCERNS?
7	DR. FLOWERS: THIS IS ELENA, WHICH IS TO
8	SAY, I GUESS JUST TO SAY I'M NOT ACTUALLY A HUGE
9	I DON'T USE A LOT OF SOCIAL MEDIA FOR MY OWN
10	SCIENCE, BUT MY EXPERIENCE IS THAT, FROM A PURELY
11	SCIENCE PERSPECTIVE, EVERYTHING MARIA JUST SAID IS
12	FAIRLY TRUE. PEOPLE ARE STILL USING X TO
13	DISSEMINATE AND SHARE INFORMATION.
14	MR. CORTEZ: I JUST WANTED TO CHIME IN IN
15	THAT ONE OF THE THINGS THAT WE ARE MONITORING
16	ACTIVELY IS JUST TAKING A LOOK AT WHAT OTHER STATE
17	ORGANIZATIONS OR SCIENCE INSTITUTIONS ARE DOING AS
18	WELL. THERE, OF COURSE, WAS SOME DROP-OFF, BUT WE
19	ARE STILL SEEING THAT A LOT OF THE MAJOR
20	INSTITUTIONS REMAIN THERE SO THAT THEY CAN HAVE SOME
21	OF THESE REAL-TIME CONVERSATIONS. AND WE ARE, OF
22	COURSE, CONTINUING TO MONITOR THAT. THANK YOU FOR
23	THAT SUGGESTION. WE ABSOLUTELY WILL MAKE A
24	STATEMENT, AND THAT'S SOMETHING THAT WE CAN POST
25	ABOUT WHY WE REMAIN ON THAT PLATFORM.

1	CAN YOU MOVE ON TO THE NEXT SLIDE,
2	CHRISTINA. WE WILL FOLLOW UP WITH SHARING THIS
3	VIDEO AS WELL WITH EVERYONE AFTER THIS MEETING.
4	JUST REALLY QUICKLY BEFORE I TRANSITION
5	OVER TO ADITI, JUST TO GIVE A QUICK UPDATE ON THE
6	PROGRESS OF THE WEBSITE, IS THAT WE, OF COURSE, HAVE
7	CONTINUED TO MOVE FORWARD WITH THIS PROJECT. WE'VE
8	BEEN WORKING ON THIS FOR MOST OF THE YEAR TO IMPROVE
9	OUR DIGITAL PRESENCE AND ENSURE THAT OUR MISSION AND
10	PROGRAMS ARE COMMUNICATED EFFECTIVELY.
11	SO IF YOU RECALL AT THE LAST MEETING, WE
12	HIGHLIGHTED THAT WE WENT THROUGH A STRATEGY AND
13	DESIGN PHASE, WHICH INCLUDED A COMPREHENSIVE AUDIT,
14	A WEB DESIGN USER INTERFACE, AND ALSO A PHASE TO
15	DEVELOP CONTENT. SO NOW WE'RE FOCUSED ON WRAPPING
16	UP THE DEVELOPMENT OF THE SITE, AND WE'RE EXCITED TO
17	SHARE A SCREENSHOT PREVIEW HERE OF THE STAGING SITE
18	OF THE WEBSITE.
19	NOW, AS YOU CAN SEE, THE HOMEPAGE HAS
20	IMPROVED NAVIGATION, MORE STREAMLINED DESIGN WHICH
21	WILL IMPROVE THE USER EXPERIENCE ONCE WE LAUNCH. SO
22	NOW WE'RE WORKING WITH THE INTERNAL TEAMS TO REVIEW
23	AND CONFIRM CONTENT FOR SPECIFIC PAGES. AND ONCE
24	SOME OF THOSE RECOMMENDATIONS ARE MADE FROM THE
25	UPCOMING STRATEGIC ALLOCATION FRAMEWORK, WE'LL MAKE

1	SURE TO ENSURE THAT ANY UPDATES ARE REFLECTED IN THE
2	CONTENT.
3	SO AS WE'RE WORKING THROUGH THIS,
4	RECOGNIZING THAT IS ALWAYS GOING TO BE AN ONGOING
5	PROJECT, WE'LL CONTINUE TO LOOK AT THE CONTENT AND
6	LOOKING FOR OPPORTUNITIES TO CONTINUE TO MAKE
7	IMPROVEMENTS TO KEEP THE SITE FRESH AND UP TO DATE.
8	I'D LIKE TO END THIS UPDATE ON THE WEBSITE
9	BY RECOGNIZING ALL OF THE TEAMS, ALL OF INTERNAL
10	STAFF WHO HAVE PROVIDED FEEDBACK AND SUPPORT WHILE
11	BALANCING SO MANY INITIATIVES THAT ARE GOING ON HERE
12	AT CIRM.
13	AND WITH THAT, I'LL GO AHEAD AND
14	TRANSITION OVER TO ADITI WHO WILL HIGHLIGHT SOME OF
15	OUR OUTREACH EFFORTS AND RECENT EVENTS.
16	MS. DESAI: THANK YOU, ESTEBAN. HOPEFULLY
17	EVERYONE CAN HEAR ME OKAY. GO ON TO THE NEXT SLIDE.
18	SO BEFORE I GO THROUGH JUST A QUICK SNAPSHOT OF SOME
19	OF THE EVENTS THAT WE'VE ATTENDED RECENTLY, I DID
20	WANT TO JUST BE RESPONSIVE TO SOME QUESTIONS THAT
21	HAVE COME UP IN TERMS OF HOW WE DECIDE WHICH EVENTS
22	TO ATTEND, WHAT KIND OF PRIORITIZATION METHOD THAT
23	WE GO THROUGH. SO YOU WILL SEE ON THIS SLIDE, ON
24	THE LEFT SIDE SPECIFICALLY, SOME PRIORITIES AND
25	CONSIDERATIONS THAT WE GO THROUGH, AND THEN THE

1	SPECIFIC STRATEGIES RELATED TO THOSE PRIORITIES.
2	SO THE FIRST ONE IS ALIGNING WITH OUTREACH
3	PRIORITIES AND CIRM-FUNDED RESEARCH. SO WE
4	PRIORITIZE EVENTS THAT ARE IDENTIFIED IN AN OUTREACH
5	CALENDAR THAT I MAINTAIN. SO IT'S A VERY LARGE
6	COMPENDIUM OF POSSIBLE EVENTS. AND THEN WE TRY TO
7	ENSURE THAT THERE'S CONSISTENCY WITHIN OUR
8	COMMUNICATIONS PLAN THAT WAS DEVELOPED AT THE
9	BEGINNING OF THE YEAR. AND WE FOCUS ON EVENTS THAT
10	ALIGN WITH RESEARCH AREAS THAT ARE FUNDED BY CIRM.
11	SO AT THOSE EVENTS WE'LL PRESENT INFORMATION ABOUT
12	HOW MUCH CIRM IS FUNDING IN THESE DISEASE AREAS.
13	WE ALSO PRIORITIZED COMMUNITY INITIATIVES.
L 4	SO PRIORITIZING INVITATIONS FROM COMMUNITY GROUPS,
15	PATIENT ADVOCACY GROUPS THAT ARE REQUESTING OUR
16	ATTENDANCE WHETHER THAT'S AT EVENTS HAVING BOOTHS OR
17	GIVING PRESENTATIONS OR TALKS.
18	WE ALSO WANT TO MAKE SURE WE'RE MAXIMIZING
19	POTENTIAL ENGAGEMENT. SO WE LOOK AT EVENTS THAT
20	GIVE US THE BEST OPPORTUNITY TO ENGAGE WITH SPECIFIC
21	COMMUNITIES THAT MIGHT BE MOST IMPACTED BY SOME OF
22	THE DISEASE AREAS THAT CIRM IS PUTTING, FUNDING
23	RESEARCH IN.
24	SO AND THEN ALSO LOOKING AT COMMUNITY
25	DIVERSITY. SO MAKING SURE THAT WE'RE EMPHASIZING
	20

1	REACHING DIVERSE COMMUNITIES, ESPECIALLY THOSE
2	SIGNIFICANTLY IMPACTED BY THE DISEASE AREAS THAT
3	WE'RE FUNDING RESEARCH IN. WE REALLY TAKE GREAT
4	PRIDE IN INVESTIGATING THE EVENT IN DETAIL AS WELL
5	AS THE ORGANIZATIONS THAT ARE HOSTING AS WELL AS
6	PRESENT AT THE EVENT JUST TO ENSURE THAT EVERYONE
7	INVOLVED ARE TRUSTED MESSENGERS THAT ALIGN WITH KIND
8	OF THE MESSAGING THAT WE WANT TO ALIGN WITH AND THEY
9	ARE TRUSTED MESSENGERS IN THESE COMMUNITIES THAT WE
10	WANT TO REACH.
11	AND THEN, OF COURSE, WE HAVE TO LOOK AT
12	THE COST OF THESE EVENTS. SO WE TAKE INTO
13	CONSIDERATION THE COST-EFFECTIVE OPTIONS. I REALLY
14	TRY TO FIND OPTIONS THAT ARE NO COST TO US BEING A
15	STATE AGENCY. BUT SOMETIMES THERE IS A MINIMAL FEE
16	THAT WE HAVE TO CONSIDER. SO WE HAVE TO LOOK AT THE
17	COST AND LOOK AT THE POTENTIAL IMPACT, THE POTENTIAL
18	ENGAGEMENT NUMBERS, AND REALLY DO A COST-BENEFIT
19	ANALYSIS TO DETERMINE IF THAT EVENT IS SOMETHING WE
20	SHOULD ATTEND.
21	MS. TEMPLE-PERRY: JUST BEFORE WE
22	TRANSITION ON, THESE ARE SOME INITIAL CONSIDERATIONS
23	IN TERMS OF PRIORITIES AND OUR STRATEGY. AND
24	OBVIOUSLY WITH ADITI'S ARRIVAL AT CIRM AND BEING HER
25	FIRST OFFICIAL OUTREACH MANAGER, THIS STRATEGY WILL

1	EVOLVE OVER TIME, AND WE WELCOME ANY FEEDBACK,
2	THOUGHTS, AND DIRECTION.
3	MS. DESAI: AS I START TO REVIEW SOME OF
4	THE EVENTS THAT WE'VE ATTENDED, I DO WANT TO
5	EMPHASIZE THAT THIS ISN'T A COMPLETE LIST OF EVENTS
6	THAT WE'VE ATTENDED RECENTLY. I'M JUST KIND OF
7	PROVIDING A SNAPSHOT OF SOME OF THE HIGH ENGAGEMENT
8	EVENTS THAT WE'VE PARTICIPATED IN TO SHARE SOME
9	OUTCOMES.
10	SO IN AUGUST WE PARTICIPATED IN THE BAY
11	AREA COMMUNITY HEALTH OHANA HEALTH AND RESOURCE
12	FAIR. THIS WAS HOSTED BY BAY AREA COMMUNITY HEALTH
13	AND THE UNLOCK ORGANIZATION. IT TOOK PLACE IN EAST
14	SAN JOSE. IT HAD AROUND 200 ATTENDEES. AT OUR
15	BOOTH WE SPECIFICALLY WE HAD AROUND 60 INTERACTIONS.
16	THE MAJORITY OF THE POPULATION THAT WERE PRESENT
17	SPOKE SPANISH OR WERE PART OF THE AAPI COMMUNITY.
18	YOU CAN GO TO THE NEXT SLIDE.
19	SO THIS WAS A REALLY GREAT EVENT. JUST
20	KIND OF ON A PERSONAL NOTE, WHEN I FIRST MOVED TO
21	CALIFORNIA, I STARTED MY CAREER WITH BAY AREA
22	COMMUNITY HEALTH. AT THE TIME IT WAS CALLED
23	TRI-CITY HEALTH CENTER. SO IT WAS REALLY GREAT TO
24	BE ATTENDING THIS EVENT AGAIN WHICH WAS PART OF MY
25	PREVIOUS ROLE AT BAY AREA COMMUNITY HEALTH. AND IT

1	WAS REALLY GREAT TO ENGAGE WITH COMMUNITIES THAT ARE
2	OFTEN UNDERSERVED, OVERLOOKED COMMUNITIES THAT DON'T
3	KNOW A LOT ABOUT REGENERATIVE MEDICINE, STEM CELL
4	RESEARCH, GENE THERAPY. SO IT WAS REALLY GREAT TO
5	BRING GENERAL FOUNDATIONAL INFORMATION TO THIS
6	COMMUNITY, BUT ALSO PROVIDE THEM WITH RESOURCES ON
7	HOW TO FIND OUT MORE, HOW TO ENGAGE POSSIBLY AND
8	LEARN MORE ABOUT CLINICAL TRIALS, LEARN MORE ABOUT
9	WHAT CIRM IS FUNDING.
10	AND ESTEBAN ATTENDED THIS EVENT WITH ME.
11	SO I ALSO WANT TO JUST OPEN THE GIVE ESTEBAN A
12	COUPLE OF MINUTES JUST TO SHARE IF HE HAD ANYTHING
13	TO ADD.
14	MR. CORTEZ: YEAH. YEAH. THANKS, ADITI.
15	ONE OF THE THINGS I REALLY WANTED TO POINT OUT IS
16	THAT IF YOU LOOK AT THE PICTURES HERE, THE PHOTO ON
17	THE LEFT WHICH HAS OUR NAME SPELLED OUT ON OUR
10	THE LEFT WHICH HAS OUR NAME SPELLED OUT ON OUR
18	CANOPY, JUST BECAUSE THIS WAS PART OF THE
18 19	
	CANOPY, JUST BECAUSE THIS WAS PART OF THE
19	CANOPY, JUST BECAUSE THIS WAS PART OF THE CONVERSATION WHEN WE WERE DECIDING ON OUR LOGO AND
19 20	CANOPY, JUST BECAUSE THIS WAS PART OF THE CONVERSATION WHEN WE WERE DECIDING ON OUR LOGO AND SPELLING OUT OUR NAME IS THAT IT'S BEEN REALLY GREAT
19 20 21	CANOPY, JUST BECAUSE THIS WAS PART OF THE CONVERSATION WHEN WE WERE DECIDING ON OUR LOGO AND SPELLING OUT OUR NAME IS THAT IT'S BEEN REALLY GREAT TO PUT SOME OF THESE NEW MATERIALS OUT THERE BECAUSE
19 20 21 22	CANOPY, JUST BECAUSE THIS WAS PART OF THE CONVERSATION WHEN WE WERE DECIDING ON OUR LOGO AND SPELLING OUT OUR NAME IS THAT IT'S BEEN REALLY GREAT TO PUT SOME OF THESE NEW MATERIALS OUT THERE BECAUSE I THINK THAT SPELLING OUT OUR NAME ACTUALLY REALLY
19 20 21 22 23	CANOPY, JUST BECAUSE THIS WAS PART OF THE CONVERSATION WHEN WE WERE DECIDING ON OUR LOGO AND SPELLING OUT OUR NAME IS THAT IT'S BEEN REALLY GREAT TO PUT SOME OF THESE NEW MATERIALS OUT THERE BECAUSE I THINK THAT SPELLING OUT OUR NAME ACTUALLY REALLY PROMPTS A LOT OF CONVERSATIONS. I EVEN RECALL EARLY

1	THAT'S SUCH A BIG WORD. WHAT DOES THAT?" SO IT
2	REALLY OPENS UP THAT CONVERSATION FOR US TO TALK
3	ABOUT IT AND HAVE AN ORGANIC CONVERSATION.
4	I WILL SAY IT WAS REALLY GREAT PRACTICE
5	FOR ME BEING A SPANISH SPEAKER, BUT NOT NECESSARILY
6	A SCIENCE SPANISH SPEAKER TO REALLY FRESHEN UP MY
7	SKILLS ON TALKING ABOUT THAT. WE GAVE OUT A TON OF
8	SPANISH ANNUAL REPORTS. AND EVEN TO WHAT ADITI SAID
9	ABOUT OUR EVENT STRATEGY, WHAT WAS REALLY GREAT
10	ABOUT THIS PARTICULAR EVENT IS THAT AT THE VERY
11	BEGINNING WE WERE ALSO ABLE TO ENGAGE WITH OTHER
12	ORGANIZATIONS WHO WERE THERE. AS AN EXAMPLE, WE
13	CONNECTED WITH AN ALZHEIMER'S ORGANIZATION THERE WHO
14	WE CONNECTED WITH AFTER THE EVENT. AND WE LEARNED
15	ABOUT OTHER UPCOMING OUTREACH OPPORTUNITIES THROUGH
16	THAT. SO REALLY GREAT EVENT. I THINK IT WAS A
17	REALLY GREAT EXAMPLE OF COMMUNITY OUTREACH AND SOME
18	OF THE GREAT CONVERSATIONS THAT WE CAN HAVE.
19	MS. TEMPLE-PERRY: THANK YOU, ESTEBAN.
20	MS. DESAI: SO THE NEXT EVENT SORRY.
21	WAS THERE A QUESTION? OKAY. SO THE NEXT EVENT I
22	WANTED TO JUST HIGHLIGHT WAS A TALK ESTEBAN AND I
23	GAVE TO THE MID-PENINSULA WIDOWS AND WIDOWERS
24	ASSOCIATION LOCATED IN LOS ALTOS.
25	SO THIS WAS AN EVENT THAT WE WERE INVITED
	22

1	TO. WE GOT AN EMAIL TO THE PRESS INBOX JUST
2	INQUIRING IF WE WERE ABLE TO GIVE A TALK TO THIS
3	GROUP. I BELIEVE THIS WAS A GROUP THAT PREVIOUSLY
4	CIRM STAFF HAD PRESENTED TO, GIVEN TALKS TO. SO
5	THEY REACHED OUT TO ASK IF WE COULD CONTINUE DOING
6	THAT. THEY SPECIFICALLY ASKED FOR INFORMATION ON
7	ANY UPDATES OR RESEARCH RELATED TO ALZHEIMER'S AND
8	PARKINSON'S DISEASE. SO WE WERE ABLE TO REALLY
9	CATER THE MESSAGING, THE TALK, THE PRESENTATION TO
10	PROVIDE THAT INFORMATION.
11	SO THERE WERE ABOUT 50 INDIVIDUALS THAT
12	ATTENDED THE MEETING, AND THE MAJORITY OF THE
13	INDIVIDUALS WERE OLDER AND PRIMARILY CAUCASIAN.
14	NEXT SLIDE.
15	SO ONE OF THE GREAT THINGS WAS REALLY
16	BEING ABLE TO ENGAGE FOLKS WHO EITHER HAD DIRECT
17	IMPACT FROM THESE DISEASE AREAS OR REALLY HAD
18	INTEREST IN LEARNING MORE ABOUT WHAT WAS GOING ON IN
19	THESE DISEASE AREAS. WE DID PROVIDE SOME OF THAT
20	BASELINE STEM CELL/GENE THERAPY EDUCATION BECAUSE
21	SOME OF THE FOLKS DIDN'T REALLY KNOW WHAT THAT
22	ENTAILED OR HAD SOME MISINFORMATION ABOUT WHAT
23	REGENERATIVE MEDICINE WAS AND REALLY KIND OF ALIGNED
24	IT MORE WITH BEAUTY AND STAYING YOUNG. SO WE REALLY
25	TRIED TO KIND OF NOT NECESSARILY LIKE TELL THEM THAT

1	THEY WERE WRONG, BUT JUST CORRECT THEM IN A GENTLE
2	WAY.
3	AND ACTUALLY IN THE AUDIENCE THERE WAS A
4	SCIENTIST, AND SINCE BOTH ESTEBAN AND I AREN'T
5	SCIENTISTS BY TRAINING, IT WAS REALLY NICE THAT
6	SCIENTIST IN THE AUDIENCE GAVE US VALIDATION, THAT
7	THE WAY WE EXPLAINED THE SCIENCE WAS ACCURATE AND
8	UNDERSTANDABLE AND RELATABLE. SO IT WAS REALLY NICE
9	GETTING THAT VALIDATION FROM AN AUDIENCE MEMBER WHO
10	WAS ALSO A SCIENTIST. AND, AGAIN, ESTEBAN, IF YOU
11	HAVE ANYTHING TO ADD, PLEASE DO.
12	MR. CORTEZ: YEAH. YEAH. I THINK THIS
13	WAS JUST AGAIN ANOTHER WONDERFUL EVENT. IT'S REALLY
14	GREAT TO SEE HOW THE CONVERSATIONS VARY BY THE
15	AUDIENCE THAT YOU TALK TO. LIKE ADITI MENTIONED,
16	THIS WAS VERY DISEASE FOCUSED, AND THEY HAD VERY
17	SPECIFIC QUESTIONS ABOUT SOME OF THE RESEARCH WE'RE
18	FUNDING, FOR EXAMPLE, IN ARTHRITIS, CLINICAL TRIALS,
19	BUT ALSO JUST QUESTIONS ABOUT ECONOMIC IMPACT.
20	AND THE LAST THING I WANT TO DRIVE THROUGH
21	WITH THIS EVENT IS THAT THIS REALLY HIGHLIGHTS HOW
22	WE COLLABORATE WITH A LOT OF THE TEAMS AT CIRM
23	BECAUSE, AGAIN, WE DON'T HAVE THAT SCIENTIFIC
24	BACKGROUND NECESSARILY. WE CONNECT WITH OTHER TEAMS
25	ON THE SCIENCE SIDE TO REALLY HELP US WITH COMING UP

1	WITH SOME TALKING POINTS AND WHAT ARE SOME OF THOSE
2	RESEARCH PROJECTS THAT WE CAN TALK ABOUT. SO I DO
3	WANT TO RECOGNIZE EVERYBODY WHO CONTRIBUTED AND WHO
4	HAS CONTRIBUTED TO THESE EVENTS AND JUST RECOGNIZE
5	THAT WE ARE REALLY WORKING TO BOOST THAT
6	COLLABORATION INTERNALLY TO MAKE SURE THAT WE ARE
7	DRIVING THE CORRECT MESSAGES.
8	MS. DESAI: ABSOLUTELY. NEXT SLIDE. AND
9	THE LAST EVENT I KIND OF WANT TO HIGHLIGHT IN DETAIL
10	IS THE NORTH BEACH FARMER'S MARKET. SO SINCE I
11	STARTED AT CIRM, ONE OF THE THINGS I REALLY WANTED
12	TO DO WAS KIND OF PUSH THE BOUNDARIES OF WHAT WE
13	THINK OF AS OUTREACH AND WHERE WE ARE PRESENT IN OUR
14	OUTREACH. SO PERSONALLY, WHEN I FIRST STARTED AT
15	CIRM, I DIDN'T HAVE A LOT OF AWARENESS ABOUT WHO
16	CIRM WAS AND WHAT WE DO. THAT WAS A LOT OF LEARNING
17	I DID BEFORE INTERVIEWING AND THEN OBVIOUSLY
18	ON-THE-JOB LEARNING.
19	SO I THINK GENERALLY WITHIN COMMUNITIES IN
20	CALIFORNIA THERE MAY NOT BE A VERY LARGE
21	UNDERSTANDING OF WHO CIRM IS, WHAT WE DO. SO THAT
22	WAS ONE OF THE REASONS WHY I REALLY WANTED TO BE IN
23	NONTRADITIONAL SPACES FOR CIRM, LIKE THESE FARMER'S
24	MARKETS, TO REALLY GET AWARENESS OF, HEY, CIRM
25	EXISTS. THIS IS WHO WE ARE. YOU MAY HAVE VOTED FOR

1	US, SO LEARN ABOUT WHAT WE'RE DOING. THIS WAS A
2	REALLY GREAT EVENT.
3	THIS WAS A FARMER'S MARKET IN SAN
4	FRANCISCO. SO WE HAD A LOT OF FOLKS, AAPI, LATINX
5	FOLKS. AND A FEW RESEARCHERS AND SCIENTISTS ALSO
6	CAME TO THE TABLE AND WERE INTERESTED TO LEARN A BIT
7	MORE. KATIE JOINED ME AT THIS EVENT. SO I KNOW
8	I WANT TO BE MINDFUL FOR TIME, BUT IF KATIE HAD ANY
9	HIGHLIGHTS OR ANYTHING SHE WANTED TO SHARE.
10	MS. SHARIFY: I THINK YOU CAPTURED
11	EVERYTHING PERFECTLY.
12	MS. DESAI: ALL RIGHT. AND THEN I JUST
13	WANTED TO
14	MS. TEMPLE-PERRY: I WAS JUST GOING TO
15	MENTION ANOTHER GREAT EVENT, WHICH IS ACTUALLY THE
16	FIRST BULLET POINT HERE, WHICH WE HAVE AS UPCOMING
17	EVENTS, BUT IT ACTUALLY JUST HAPPENED THIS PAST
18	WEEKEND, WAS OUR PRESENCE AT THE KITS CUBED STEM
19	FAIR WHICH TOOK PLACE AT OAKLAND TECHNICAL HIGH
20	SCHOOL. AND WE HAD A LOT OF FOLKS FROM OUR TEAM
21	THERE. IT WAS VERY, VERY POPULAR. WE FEATURED DNA
22	BRACELET MAKING. WE HAD A NUMBER OF COLORING PAGES,
23	CROSSWORD PUZZLES WHICH ADITI HAS BEEN INSTRUMENTAL
24	IN DEVELOPING. IT WAS VERY, VERY POPULAR. IT WAS
25	AN ALL DAY EVENT, AND OUR BOOTH WAS VERY, VERY

1	POPULAR. WE WERE QUITE TIRED AT THE END OF THAT.
2	BUT I DEFINITELY WANT TO RECOGNIZE ADITI FOR MOVING
3	THAT PROCESS FORWARD. IT WAS REALLY COLLABORATIVE.
4	AND SO, ADITI, I DON'T KNOW IF THERE'S ANYTHING ELSE
5	YOU WANTED TO MENTION ABOUT THAT.
6	MS. DESAI: YEAH. SO WE HAVE THIS LISTED
7	AS AN UPCOMING EVENT JUST BECAUSE IT LITERALLY JUST
8	HAPPENED THIS PAST WEEKEND. BUT THIS EVENT IS THE
9	ANNUAL EVENT WITH THE KITS CUBED ORGANIZATION. AN
10	ALUMNI FROM OAKLAND TECH STARTED THIS ORGANIZATION,
11	AND THIS IS THEIR BIGGEST EVENT THROUGHOUT THE YEAR.
12	THE EVENT REALLY TRIES TO HONE IN ON
13	REACHING COMMUNITIES THAT ARE OVERLOOKED AND
14	UNDERSERVED IN THE SPACES OF STEM AND REALLY
15	ENCOURAGE YOUTH FROM THOSE COMMUNITIES, VERY
16	SPECIFICALLY BLACK AFRICAN-AMERICAN COMMUNITIES AND
17	ALSO LATINX COMMUNITIES, TO ENGAGE IN STEM
18	ACTIVITIES AND TO GET EXCITED ABOUT STEM SUBJECTS.
19	SO THE EVENT REALLY HAS INTERACTIVE
20	EXPERIMENTS. SO MOST OF THE BOOTHS HAVE SOMETHING
21	INTERACTIVE. AND SO WHEN WE WENT LAST YEAR, IT WAS
22	RIGHT AFTER I STARTED. SO WE DIDN'T HAVE A LOT OF
23	TIME TO CREATE THESE HANDS-ON ACTIVITIES, BUT THIS
24	YEAR IT WAS REALLY EXCITING TO HAVE DNA BRACELET
25	MAKING, THE PLINKO BOARD, AS WELL AS SOME COLORING

1	SHEETS. AND I WILL HAVE TO SAY THERE WAS A POINT
2	WHERE WE GOT SWARMED BY CHILDREN, AND IT WAS
3	OVERWHELMING IN THE BEST WAY POSSIBLE BECAUSE THE
4	KIDS WERE REALLY, REALLY ENGAGED. AND NOT JUST ON
5	MAKING THE BRACELET, BUT REALLY INTERESTED IN
6	LEARNING WHAT THE BRACELET WAS.
7	SO WE HAD THE DNA SEQUENCE FOR DIFFERENT
8	ANIMALS, AND THEY WERE ABLE TO PICK THEIR FAVORITE
9	ANIMALS OUT OF THAT LIST AND MAKE A DNA BRACELET
10	THAT REPRESENTED THE DNA OF THAT ANIMAL. IT WAS
11	JUST REALLY GREAT TO SEE THAT LEVEL OF ENGAGEMENT.
12	AND, OF COURSE, THEIR PARENTS AND GUARDIANS
13	INTERACTED WITH US IN TERMS OF CIRM, LEARNING ABOUT
14	CIRM PROGRAMMING, ESPECIALLY THE EDUCATIONAL
15	PROGRAMS.
16	I WANT TO GIVE A BIG SHOUT-OUT TO DAISY
17	FOR HELPING DEVELOP THESE HANDS-ON ACTIVITIES. I
18	THINK WITHOUT HER, I WOULD NOT BE ABLE TO EXPLAIN IT
19	AS WELL AS I DID. SO THANK YOU.
20	MS. TEMPLE-PERRY: THANKS ALSO TO A NUMBER
21	OF THE CIRM SPOUSES AND PARTNERS. WE DID HAVE A
22	NICE ORGANIZED FASHION OF PULLING THINGS TOGETHER,
23	PACKING IT UP. AND THERE WERE A NUMBER OF FOLKS
24	FROM CIRM WHO CAME BY, BROUGHT THEIR KIDS. I PUT MY
25	DAUGHTER TO WORK.

1	MS. DESAI: ABSOLUTELY. ABSOLUTELY. AND
2	THEN JUST TO HIGHLIGHT SOME UPCOMING EVENTS. SO
3	THROUGH THE OHANA FAIR THAT WE ATTENDED IN AUGUST,
4	WE WERE ABLE TO CONNECT WITH THE ALZHEIMER'S
5	ASSOCIATION. AND WE SECURED A BOOTH AT THE
6	FRESNO/MADERA ALZHEIMER'S ASSOCIATION WALK. AND
7	THEN I'VE ALSO BEEN WORKING TO REACH OUT TO VARIOUS
8	ROTARY CLUBS, SPECIFICALLY IN THE BAY AREA, BUT ALSO
9	THROUGHOUT THE STATE WITH THE HELP OF JACQUELINE TO
10	SECURE DATES AND TIMES TO HAVE SOME PRESENTATIONS,
11	SOME TALKS JUST TO SHARE ABOUT CIRM, WHO WE ARE,
12	WHAT WE DO. AND ALSO, SIMILAR TO THAT LOS ALTOS
13	TALK, MAYBE PROVIDE SOME SPECIFIC DISEASE AREA
14	INFORMATION SHOULD THEY REQUEST IT.
15	WE ALSO HAVE SOME EVENTS HAPPENING IN
16	SOUTHERN CALIFORNIA THAT ARE COMING UP. SO RIGHT
17	NOW JACQUELINE IS ATTENDING THE SICKLE CELL DISEASE
18	EDUCATIONAL SUMMIT THAT IS GOING THROUGH THE END OF
19	THE WEEK. AND THEN WE ALSO HAVE THE VISION WALK
20	THAT'S TAKING PLACE OCTOBER 26TH. THAT'S WITH THE
21	FOUNDATION FOR FIGHTING BLINDNESS. AND THEN FINALLY
22	WE HAVE OUR WORLD AIDS DAY EVENT WHICH WILL BE
23	TAKING PLACE IN PALM SPRINGS THAT JACQUELINE WILL BE
24	ATTENDING IN DECEMBER. I KNOW THAT WAS A LOT.
25	THANK YOU SO MUCH.

1	MS. TEMPLE-PERRY: THAT BRINGS US TO THE
2	END OF OUR PRESENTATION. AND WE JUST WANTED TO OPEN
3	THE FLOOR. IF YOU HAVE FEEDBACK, THOUGHTS,
4	QUESTIONS, WE'RE OPEN TO THAT.
5	CHAIRPERSON BONNEVILLE: YSABEL, PLEASE.
6	MS. DURON: I WAS JUST WONDERING, WHENEVER
7	YOU TALK TO WHOMEVER YOU SPEAK WITH, DO YOU TELL
8	THEM THAT THIS IS TAXPAYER FUNDED AND THANK YOU VERY
9	MUCH?
10	MS. DURON: ALL THE TIME?
11	MS. DESAI: YES. EVERY TIME. SO THAT'S
12	PART OF MY I'LL SPEAK FOR MYSELF. WHENEVER I'M
13	IN THE COMMUNITY, THAT'S PART OF MY KIND OF SPIEL OR
14	ONE OF THREE VERSIONS OF THE SPIEL IS WE'RE A
15	VOTER-APPROVED, STATE-FUNDED AGENCY. THAT'S ONE OF
16	THE VERY FIRST THINGS I SAY AFTER EXPLAINING WHAT
17	CIRM STANDS FOR. SO, YES, DEFINITELY THAT'S A KEY
18	PART OF THE MESSAGING.
19	MS. DURON: DO THEY RESPOND? IN OTHER
20	WORDS, OH, I DIDN'T KNOW THAT?
21	MS. DESAI: YEAH. SOMETIMES THEY'LL ASK
22	LIKE, OH, WHAT DOES THAT MEAN? SO THEN I'LL TALK
23	ABOUT THE PROPOSITIONS AND TRY AND SEE IF THEY MIGHT
24	VAGUELY REMEMBER EITHER OF THE PROPOSITIONS. BUT
25	YEAH, SOMETIMES. MOST OF THE TIME THEY ARE LIKE,
	4.1

1	OH, OKAY. COOL.
2	MR. CORTEZ: I CAN CHIME IN TOO BECAUSE
3	HAVING BEEN AT SOME OF THESE EVENTS, USING KITS
4	CUBED EVENT IN OAKLAND AS AN EXAMPLE. THAT'S ALSO
5	PART OF MY PITCH. SO I WILL SPEAK FOR MYSELF AND I
6	THINK REALLY FOR MOST OF THE TEAM. I WANT TO MAKE
7	SURE WE MENTION THAT.
8	BUT IN MANY CASES THERE ARE QUESTIONS
9	ABOUT, OKAY, WELL, YOU'RE TAXPAYER FUNDED. WHAT ARE
10	SOME OF THE RESULTS? AND WE'RE ABLE TO TALK ABOUT
11	THE PROGRESS AND THE RESEARCH, SOME OF THE CLINICAL
12	TRIALS WE'VE FUNDED, BUT ALSO THIS OPENS UP THE
13	DISCUSSION FOR ECONOMIC IMPACT. WE HAVE OUR
14	ECONOMIC IMPACT REPORT FROM A FEW YEARS BACK. SO
15	WE'RE ABE TO REALLY HIGHLIGHT HOW CIRM HAS CREATED
16	THIS ECOSYSTEM IN CALIFORNIA. SO IT REALLY OPENS UP
17	THAT CONVERSATION. SO WE DO MAKE THAT SURE THAT
18	WE'RE ALWAYS MENTIONING AND HIGHLIGHTING THAT WE ARE
19	FUNDED BY THE PEOPLE OF CALIFORNIA.
20	MS. TEMPLE-PERRY: AND TO YOUR POINT,
21	YSABEL, MOST OF THE CONVERSATIONS THAT WE HAVE ARE
22	REALLY ORGANIC WHICH IS THE BEAUTY OF IT ALL. AND
23	PEOPLE ARE REALLY THANKFUL. EVERY TIME I THINK I'VE
24	HAD CONVERSATIONS, THEY THANK US FOR COMING OUT
25	THERE. THEY THANK US FOR OUR PRESENCE AND JUST

1	ENGAGING WITH THE COMMUNITY.
2	MS. DURON: THAT'S NICE TO HEAR.
3	CHAIRPERSON BONNEVILLE: ARE THERE ANY
4	OTHER QUESTIONS OR COMMENTS? I HAVE ONE, BUT I WANT
5	TO LET OTHER BOARD MEMBERS ASK THEIR QUESTIONS OR
6	MAKE THEIR COMMENTS. OKAY.
7	CHRISTINA, THIS IS FOR YOU. I WOULD LOVE
8	IT IF EITHER AT THE NEXT, NOT NEXT WEEK'S BOARD
9	MEETING BECAUSE THAT'S NEXT WEEK, BUT AT THE NEXT
10	COMMUNICATIONS SUBCOMMITTEE MEETING AND THEN LIKELY
11	THE DECEMBER BOARD MEETING, I WOULD LOVE TO TALK
12	MORE ABOUT OUR SOCIAL MEDIA STRATEGY, WHO WE TALK TO
13	ON THAT, HOW OFTEN. LIKE I HAVE QUESTIONS, FOR
14	EXAMPLE, AT THE TRAINEE CONFERENCE, WOULD WE EVER DO
15	LIKE A LIVE INSTAGRAM REEL DURING THAT TIME OR A
16	STORY I'M NOT SPEAKING THE RIGHT WORDS. YOU KNOW
17	WHAT I'M TRYING TO SAY. I'M OLD. SO I'D LOVE TO
18	HEAR ABOUT THAT AND JUST SORT OF WHAT OUR THOUGHTS
19	ARE AROUND THAT.
20	MS. SMITH: SURE.
21	CHAIRPERSON BONNEVILLE: ANYTHING ELSE?
22	ANYONE, ANYONE? IS THERE ANY PUBLIC COMMENT?
23	MS. MANDAC: NO HANDS RAISED.
24	MS. DESAI: CAN I JUST SAY ONE THING?
25	CHAIRPERSON BONNEVILLE: OF COURSE YOU

CAN.
MS. DESAI: I JUST WANT TO THANK ALL THE
BOARD MEMBERS WHO HAVE VOLUNTEERED. I KNOW SOME OF
YOU VOLUNTEERED TO ATTEND EVENTS AND HAD TO BACK OUT
LAST MINUTE FOR PERSONAL REASONS, WHICH ARE TOTALLY
UNDERSTANDABLE, BUT I DO WANT TO THANK YOU SO MUCH
FOR EVEN JUST GIVING THE POSSIBILITY OF YOUR TIME.
AND I WILL CONTINUE TO WORK WITH CLAUDETTE TO GET
INFORMATION ABOUT EVENTS OUT THERE TO HOPEFULLY SEE
IF YOU ALL CAN JOIN BECAUSE IT'S REALLY GREAT HAVING
BOARD MEMBERS ATTEND AND JUST TO SEE THE OUTREACH
AND THE WAY THE COMMUNITY IS RECEIVING US. SO JUST
WANTED TO MENTION THAT.
CHAIRPERSON BONNEVILLE: ALL RIGHT. WITH
THAT, WE CAN ADJOURN THE MEETING. AND THANK YOU SO
MUCH. YOU GET THREE MINUTES BACK.
(THE MEETING WAS THEN CONCLUDED AT 3:57 P.M.)
44

1	
2	
3	REPORTER'S CERTIFICATE
4	
5	
6	I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN
7	AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE VIRTUAL PROCEEDINGS
8	BEFORE THE COMMUICATIONS SUBCOMMITTEE OF THE INDEPENDENT CITIZEN'S OVERSIGHT COMMITTEE OF THE
9	CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE IN THE MATTER OF ITS REGULAR MEETING HELD ON SEPTEMBER
10	18, 2024, WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE
11	STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE REPORTED STENOGRAPHICALLY BY ME AND TRANSCRIBED BY
12	ME. I ALSO CERTIFY THAT THIS TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.
13	AND ACCORATE RECORD OF THE PROCEEDING.
14	
15	
16	BETH C. DRAIN, CA CSR 7152 133 HENNA COURT
17	SANDPOINT, IDAHO (208) 920-3543
18	(200) 320 3313
19	
20	
21	
22	
23	
24	
25	
	45